These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 21455197

  • 41. Can noninvasive follicular thyroid neoplasm with papillary-like nuclear features be distinguished from classic papillary thyroid carcinoma and follicular adenomas by fine-needle aspiration?
    Brandler TC, Zhou F, Liu CZ, Cho M, Lau RP, Simsir A, Patel KN, Sun W.
    Cancer Cytopathol; 2017 Jun; 125(6):378-388. PubMed ID: 28296267
    [Abstract] [Full Text] [Related]

  • 42. Can CD10 be used as a diagnostic marker in thyroid pathology?
    Yegen G, Demir MA, Ertan Y, Nalbant OA, Tunçyürek M.
    Virchows Arch; 2009 Jan; 454(1):101-5. PubMed ID: 19031085
    [Abstract] [Full Text] [Related]

  • 43. Problems and controversies in the histopathology of thyroid carcinomas of follicular cell origin.
    Ghossein R.
    Arch Pathol Lab Med; 2009 May; 133(5):683-91. PubMed ID: 19415942
    [Abstract] [Full Text] [Related]

  • 44. Lymphatic and blood vessel density in the follicular patterned lesions of thyroid.
    Giorgadze TA, Baloch ZW, Pasha T, Zhang PJ, Livolsi VA.
    Mod Pathol; 2005 Nov; 18(11):1424-31. PubMed ID: 15920537
    [Abstract] [Full Text] [Related]

  • 45. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
    Jung CK, Kim Y, Jeon S, Jo K, Lee S, Bae JS.
    Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
    [Abstract] [Full Text] [Related]

  • 46. Clear Cell Variant of a Follicular Thyroid Tumor With Uncertain Malignant Potential: A Case Report.
    Juhlin CC, Bränström R, Shabo I, Höög A.
    Int J Surg Pathol; 2019 May; 27(3):290-293. PubMed ID: 30370813
    [Abstract] [Full Text] [Related]

  • 47. Diagnostic and prognostic implications of the PAX8-PPARγ translocation in thyroid carcinomas-a TMA-based study of 226 cases.
    Boos LA, Dettmer M, Schmitt A, Rudolph T, Steinert H, Moch H, Sobrinho-Simões M, Komminoth P, Perren A.
    Histopathology; 2013 Aug; 63(2):234-41. PubMed ID: 23738683
    [Abstract] [Full Text] [Related]

  • 48. Decreased relative expression level of trefoil factor 3 mRNA to galectin-3 mRNA distinguishes thyroid follicular carcinoma from adenoma.
    Takano T, Miyauchi A, Yoshida H, Kuma K, Amino N.
    Cancer Lett; 2005 Feb 28; 219(1):91-6. PubMed ID: 15694668
    [Abstract] [Full Text] [Related]

  • 49. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.
    Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M.
    Exp Oncol; 2006 Mar 28; 28(1):70-4. PubMed ID: 16614712
    [Abstract] [Full Text] [Related]

  • 50. [Recently identified renal cell carcinoma].
    Zhao M, Teng XD, Sun K, Cheng L.
    Zhonghua Bing Li Xue Za Zhi; 2013 Jul 28; 42(7):478-82. PubMed ID: 24246873
    [No Abstract] [Full Text] [Related]

  • 51. Follicular Thyroid Neoplasms: Comparison of Clinicopathologic and Molecular Features of Atypical Adenomas and Follicular Thyroid Carcinomas.
    Cracolici V, Ritterhouse LL, Segal JP, Puranik R, Wanjari P, Kadri S, Parilla M, Cipriani NA.
    Am J Surg Pathol; 2020 Jul 28; 44(7):881-892. PubMed ID: 32282345
    [Abstract] [Full Text] [Related]

  • 52. Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications.
    Menon MP, Khan A.
    J Clin Pathol; 2009 Nov 28; 62(11):978-85. PubMed ID: 19625289
    [Abstract] [Full Text] [Related]

  • 53. CITED1 protein expression suggests Papillary Thyroid Carcinoma in high throughput tissue microarray-based study.
    Prasad ML, Pellegata NS, Kloos RT, Barbacioru C, Huang Y, de la Chapelle A.
    Thyroid; 2004 Mar 28; 14(3):169-75. PubMed ID: 15072698
    [Abstract] [Full Text] [Related]

  • 54. Follicular thyroid lesions, elements that affect both diagnosis and prognosis.
    Zeiger MA, Dackiw AP.
    J Surg Oncol; 2005 Mar 01; 89(3):108-13. PubMed ID: 15719377
    [Abstract] [Full Text] [Related]

  • 55. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
    Buergy D, Weber T, Maurer GD, Mudduluru G, Medved F, Leupold JH, Brauckhoff M, Post S, Dralle H, Allgayer H.
    Int J Cancer; 2009 Aug 15; 125(4):894-901. PubMed ID: 19480010
    [Abstract] [Full Text] [Related]

  • 56. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
    Pyo JS, Kim DH, Yang J.
    Int J Biol Markers; 2018 May 15; 33(2):161-167. PubMed ID: 29799356
    [Abstract] [Full Text] [Related]

  • 57. HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm.
    Mase T, Funahashi H, Koshikawa T, Imai T, Nara Y, Tanaka Y, Nakao A.
    Endocr J; 2003 Apr 15; 50(2):173-7. PubMed ID: 12803237
    [Abstract] [Full Text] [Related]

  • 58. Follicular neoplasm of the thyroid--vanishing cytologic diagnosis?
    Kapur U, Wojcik EM.
    Diagn Cytopathol; 2007 Aug 15; 35(8):525-8. PubMed ID: 17636488
    [Abstract] [Full Text] [Related]

  • 59. Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma.
    Umbricht CB, Saji M, Westra WH, Udelsman R, Zeiger MA, Sukumar S.
    Cancer Res; 1997 Jun 01; 57(11):2144-7. PubMed ID: 9187112
    [Abstract] [Full Text] [Related]

  • 60. Trefoil factor 3 (TFF3): a promising indicator for diagnosing thyroid follicular carcinoma.
    Takano T, Yamada H.
    Endocr J; 2009 Jun 01; 56(1):9-16. PubMed ID: 18506086
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.